Strain Data Sheet
RBRC01270
Strain Information | |
|---|---|
| Image | |
| BRC No. | RBRC01270 |
| Type | Targeted Mutation |
| Species | Mus musculus |
| Strain name | B6;129-Gnptab<tm1Zili>/SiecRbrc |
| Former Common name | Stealth [lacZloxPneoRloxP/+] |
| H-2 Haplotype | |
| ES Cell line | |
| Background strain | 129 |
| Appearance | |
| Strain development | Targeting of Stealth: 2001, Denis-Luc Ardiet, ISREC |
| Strain description | Mice with a lacZ knock-in in the first major coding exon of Stealth. The lacZ ORF begins with the first start codon of that stealth exon. Purpose of that mouse strain is to analyze stealth function in mice, in particular for its role in development, innate immunity, and homeostasis of organ systems.PGKneoR cassette flanked with loxP sites still present in this stealth null allele because these mice haven't been crossed with a deleter strain since there hasn't been one isogenic for 129SvEv(Allan Bradley). |
| Colony maintenance | This strain has been kept isogenic for the genetic background 129SvEv (source: Allan Bradley) that is the very same genetic background of the ES cells in which the Stealth null allele was generated by a knock-in of lacZ in frame wih the major first start codon of Stealth. Hence, this precious isogenic line shall be kept breeding in its literally original background. In particular, the Stealth null allele is homozygous viable when isogenic for 129SvEv. However, such homozygotes don't breed, become sick with age and develop so far uncharacterized inflammatory processes and cachexia. |
| References | |
Health Report | |
|---|---|
| Examination Date / Room / Rack | |
Gene | |
|---|---|
| Gene info | Gene symbolGene nameChr.Allele symbolAllele nameCommon namesPromoter GnptabN-acetylglucosamine-1-phosphate transferase, alpha and beta subunits10Gnptab<tm1Zili>targeted mutation 1, Olav Zilian Gene symbolGene nameChr.Allele symbolAllele nameCommon namesPromoter lacZbeta-galactosidase (E. coli)10 Gene symbolGene nameChr.Allele symbolAllele nameCommon namesPromoter loxPphage P1 loxP10loxP Gene symbolGene nameChr.Allele symbolAllele nameCommon namesPromoter loxPphage P1 loxP10loxP Gene symbolGene nameChr.Allele symbolAllele nameCommon namesPromoter neoneomycin resistance gene (E. coli)10neo; neomycin; |
Ordering Information | |
|---|---|
| Donor DNA | E. coli lacZ, E. coli neo, mouse stealth genomic DNA, SV40-3' UTR, phage P1 loxP |
| Research application | Cell Biology Research |
| Specific Term and Conditions | The RECIPIENT of BIOLOGICAL RESOURCE shall obtain a prior written consent on use of it from the DEPOSITOR. In publishing the research results obtained by use of the BIOLOGICAL RESOURCE, a citation of the following literature(s) designated by the DEPOSITOR is requested. To be cited is any publication by the DEPOSITOR describing the BIOLOGICAL RESOURCE for the first time. This term is to be respected in particular when the first 2 years after deposition of the BIOLOGICAL RESOURCE are passed.In publishing the research results to be obtained by use of the BIOLOGICAL RESOURCE, an acknowledgment to the DEPOSITOR is requested. This term is to be respected in particular when the material was requested after the first 2 years upon deposition of the BIOLOGICAL RESOURCE.1) The RECIPIENT agrees to use this BIOLOGICAL RESOURCE as a collaboration with the DEPOSITOR. Furthermore, the RECIPIENT agrees to include the DEPOSITOR as a co-author in any publications resulted by the use of the BIOLOGICAL RESOURCE in research projects initiated during the first 2 years after deposition by the DEPOSITOR to the RIKEN BRC. 2) Further, the RECIPIENT must inform the DEPOSITOR about the research project using the BIOLOGICAL RESOURCE and must obtain a prior permission from the DEPOSITOR to avoid the conflict of interest with the DEPOSITOR. 3)Furthermore, prior to filing an application for a patent, or intellectual property or other rights based on the results of research using the BIOLOGICAL RESOURCE, the RECIPIENT shall acquire the consent from the DEPOSITOR for such application. |
| Depositor | Olav Zilian (Institut Suisse de Recherche Experimentale sur le Cancer (ISREC)) |
| Strain Status |  Frozen sperm |
| Strain Availability | Recovered litters from cryopreserved sperm (2 to 4 months) Cryopreserved sperm (within 1 month) |
| Additional Info. | Necessary documents for ordering:
Genotyping protocol -PCR- |
BRC mice in Publications |
|---|
| No Data |